Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Geographic Atrophy

Eye & Vision

Geographic Atrophy (GA) Clinical Trials and Treatments

Also called GA, advanced dry AMD, dry age-related macular degeneration, advanced dry macular degeneration

Geographic atrophy is the late-stage form of dry age-related macular degeneration, distinct from the wet (neovascular) form. It is characterized by well-demarcated areas of retinal pigment epithelium (RPE) atrophy in the macula, the central region of the retina responsible for sharp, detailed vision. As RPE cells degenerate, the overlying photoreceptors lose metabolic support and die, creating expanding zones of irreversible vision loss.

In plain words, geographic atrophy is an advanced form of dry age-related macular degeneration, where patches at the back of the eye wear away. Sharp central vision used for reading and seeing faces slowly fades, and the lost vision does not come back.

Get an email when new Geographic Atrophy trials open or the FDA decides. Get alerts

Geographic Atrophy

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review0

No decision pending. FDA calendar

FDA-approved medicines2

Izervay · Syfovre

Geographic Atrophy has 2 FDA-approved medicines, 52 open or active clinical trials, and no pending FDA decision.

Labels checked October 21, 2026. Corticosteroids and immune globulins count once each.Download the data

Latest for Geographic Atrophy

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Geographic Atrophy

The pathophysiology involves dysregulation of the complement system, a component of innate immunity, which drives chronic inflammation and progressive destruction of retinal tissue. Drusen (deposits of lipid and protein beneath the RPE) accumulate and activate complement cascades.

Keep reading about Geographic Atrophy

The first FDA-approved treatments specifically for geographic atrophy target this complement pathway: pegcetacoplan (SYFOVRE, Apellis) inhibits C3, and avacincaptad pegol (IZERVAY, Astellas/Iveric Bio) inhibits C5. Both are administered as intravitreal injections and have been shown to slow the rate of atrophy expansion, though they do not restore lost vision.

Geographic atrophy typically progresses over years, and maintaining regular monitoring with optical coherence tomography (OCT) is essential for tracking disease progression.

Why is Geographic Atrophy on Trial Friend?Geographic atrophy affects approximately 1 million people in the U.S., exceeding the rare disease threshold. It is included on Trial Friend because complement-targeted therapies represent a new treatment paradigm with active clinical development.

What are the symptoms of Geographic Atrophy?

These are common symptoms of Geographic Atrophy, and how strong they are varies from person to person.

  • Dark or blank spots in the center of vision
  • Difficulty reading or seeing fine details
  • Colors appearing drab or less vibrant
  • Difficulty seeing in dim lighting
  • Gradual loss of central vision sharpness
  • Increased difficulty recognizing faces

Who gets Geographic Atrophy?

Primarily affects adults over 60, with risk increasing significantly with age. More common in women and those of European descent. Risk factors include smoking, family history of AMD, cardiovascular disease, and UV light exposure.

Next steps: find trials you might fitsee approved treatmentsget help payingget alerts

Which medicines are FDA-approved for Geographic Atrophy?

There are currently 2 FDA-approved medications for Geographic Atrophy.

avacincaptad pegol
Astellas Pharma (developed by Iveric Bio, which Astellas acquired in July 2023)
Search
pegcetacoplan injection (intravitreal)

Source: openFDA drug labeling data. This list may not include all treatments. Always consult your doctor.

Which new Geographic Atrophy medicines are in trials?

Investigational medicines Trial Friend tracks for Geographic Atrophy, with trial results, safety findings and where each one stands.

How to get help paying for Geographic Atrophy treatment

Charity funds and drugmaker programs for Geographic Atrophy, checked at the source.

Which insurance do you have? Pick one to see what fits. Tap it again to clear.
Your insurance
Drugmaker programs
Open a medicine for who qualifies, by insurance type.

Every program and fund for Geographic Atrophy, by insurance →

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Geographic Atrophy

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Geographic Atrophy resources

Reputable organizations and medical references for learning more about Geographic Atrophy, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Geographic Atrophy

Use this Geographic Atrophy clinical trial finder to see the 19 studies recruiting patients and 1 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 19 test a treatment and 1 is an observational study or registry; each card says which. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map, the pipeline timeline or the medication checker.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

52 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 2Recently updatedNCT07851259

A Study to Assess the Efficacy and Safety of RO7965032 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Intervention: RO7965032, Placebo

Sponsor: Genentech, Inc.

This study will assess the safety and efficacy of RO7965032 to address a significant unmet medical need in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Ages 50 Years+
Expected to start Jan 2027Updated 2 days agoEst. Aug 2030 (~3y 9m)
RecruitingTreatment trialPhase 1Recently updatedNCT03178149

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Intervention: ASP7317, tacrolimus, trimethoprim-sulfamethoxazole, Acyclovir, Nystatin

Sponsor: Astellas Institute for Regenerative Medicine

Age-related macular degeneration (AMD) is an eye disease which causes people to lose their sharp central vision over time. Aging damages the macula, which is in the middle of the retina - the light-sensitive part at the back of the eye. There are 2 types of AMD - wet AMD and dry ...

Ages 50 Years+
Started Jan 2019Updated 3 days agoEst. Dec 2027 (~1y 1m)
RecruitingTreatment trialPhase 2Recently updatedNCT05626114

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

Intervention: OpRegen

Sponsor: Genentech, Inc.

This study will evaluate the success and safety of subretinal surgical delivery as well as the preliminary activity of OpRegen in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). All endpoints are assessed for the study eye unless otherwise indicated.

Ages 50 Years+
Started Mar 2023Updated 6 days agoEst. Mar 2031 (~4y 3m)
RecruitingTreatment trialPhase 2Recently updatedNCT06990269

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

Intervention: ADX-038, Placebo

Sponsor: ADARx Pharmaceuticals, Inc.

Phase 2 study is designed to assess the efficacy of ADX-038 compared with placebo in participants with GA secondary to AMD. Safety, pharmacokinetics (PK), and pharmacodynamics (PD) will also be assessed.

Ages 60 Years+
Started Nov 2025Updated 1 week agoEst. Feb 2030 (~3y 3m)
RecruitingTreatment trialPhase 1/2Recently updatedNCT04339764

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

Intervention: iPSC-derived RPE/PLGA transplantation

Sponsor: National Eye Institute (NEI)

Background:

Age-related macular degeneration is a common eye disease in people over 50. The "dry" form of the disease can worsen into geographic atrophy, causing blind spots. Researchers want to learn if replacing older eye cells with younger ones can help treat this disease.

Ages 55 Years to 95 Years2 locations
Started Sep 2020Updated 1 week agoEst. May 2029 (~2y 6m)
Find Geographic Atrophy trials near you, ranked by distance →
Active trial locations182 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+174 more

Trial Pipeline

Jan 2021 to Nov 2031; studies that began earlier start at the left edge
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Geographic Atrophy trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Geographic Atrophy foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Geographic Atrophy patient communities

Facebook groups, Reddit communities and YouTube channels where Geographic Atrophy patients, caregivers and advocacy groups talk.

Companies developing Geographic Atrophy treatments

Drugmakers that list Geographic Atrophy in their rare disease portfolio, with makers of its treatments first.

Questions people ask about Geographic Atrophy